We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Congenital Toxoplasmosis Diagnosed Early By Molecular Test

By LabMedica International staff writers
Posted on 22 Sep 2011
A molecular test has been validated as a method to affirm the diagnosis of congenital toxoplasmosis (CT) using neonatal peripheral blood.

A polymerase chain reaction (PCR) assay was found to be a sensitive, rapid, and cost-effective method to affirm the diagnosis of previously undiagnosed congenital toxoplasmosis using blood from very young infants.

Scientists at the University of Montpellier I (France) prospectively enrolled all successive neonates who had blood sampled for molecular diagnosis of CT before the age of three weeks from March 2003 to December 2008, in the Languedoc-Roussillon region, in southern France. More...
A series of tests were performed on amniotic fluid, placenta, and cord blood by a highly performing conventional PCR that has shown excellent sensitivity as compared with other real-time PCR assays and mice inoculation. Serologic follow-up during the first year of life for immunoglobulin (Ig) IgG, IgM, and IgA by enzyme linked immunosorbent assay (ELISA), immunofluorescence, and/or immunosorbent agglutination assay (ISAGA), and comparative immune charge relating specific IgG to total IgG.

In a cohort of 12 consecutive neonates, the PCR assay established the diagnosis of five of six cases of congenital toxoplasmosis and did so earlier than serologic methods. In all cases of CT, the maternal infection occurred in the third trimester. The PCR tests were performed using neonatal peripheral blood on day-two to day-four for eight cases, one case on day 10 and three cases on day 15. The PCR was positive in 83% of the cases of CT and negative in the remaining cases. In one neonate, the positive PCR using peripheral blood was the first test, which affirmed the diagnosis of CT. In the cohort, one false-negative molecular test was recorded, emphasizing that the diagnosis of CT is difficult and often needs a combination of laboratory tests.

The authors concluded that with a low false-negative rate and no false-positive result, PCR on neonatal peripheral blood was validated as it can be performed routinely. The assay is able to affirm the diagnosis of CT and perhaps render the first positive result. The study was published on August 8, 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
University of Montpellier I



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.